Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction

Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction

Aim. To study the levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with acute myocardial infarction (MI).Material and methods. The study included 74 patients with acute MI. PCSK9 was determined by enzyme-linked immunosorbent assay.Results. The mean PCSK9 levels were 479,7±...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. D. Gimadeeva, A. S. Galyavich, Z. M. Galeeva, L. V. Baleeva
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2020-03-01
Series:	Российский кардиологический журнал
Subjects:	proprotein convertase subtilisin/kexin type 9 myocardial infarction
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/3724
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING
by: K. S. Benimetskaya, et al.
Published: (2019-03-01)

Novel insights into the association between genetically proxied inhibition of proprotein convertase subtilisin/kexin type 9 and risk of sarcopenia
by: Hongyan Jiang, et al.
Published: (2024-12-01)

The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk
by: Natalie Schellack, et al.
Published: (2016-01-01)

Subtilisin/kexin type 9 protein convertase and interleukin 1 beta alterations in acute myocardial infarction
by: Michał Majewski, et al.
Published: (2025-05-01)

PCSK9 in acute coronary syndrome: analysis of associations with clinical and laboratory characteristics
by: Yu. A. Drenina, et al.
Published: (2020-09-01)

Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease
by: Haixia Tang, et al.
Published: (2025-08-01)

Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− mice
by: Xiaocui Chen, et al.
Published: (2025-03-01)

PCSK9 Inhibitors: The Evolving Future
by: Bijay Mukesh Jeswani, et al.
Published: (2024-11-01)

The importance of paying attention to the role of lipid-lowering drugs in controlling dengue virus infection
by: Omer Qutaiba B. Allela, et al.
Published: (2024-12-01)

Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases
by: Zhenzhen Li, et al.
Published: (2024-11-01)

Human PCSK9D374Y exacerbates methionine choline deficiency diet-induced nonalcoholic steatohepatitis in mice
by: Abidan·ABUDURUSULI, CHEN Xiaocui, CUI Yuanfeng, Tuoluonayi·MIJITI, DENG Lihui, CHEN Bangdang
Published: (2025-05-01)

Oral and Non-Oral Cholesterol-Lowering Drugs with PCSK9 and Other Biomolecules as Targets: Present Status and Future Prospects
by: Ajoy Basak
Published: (2025-03-01)

Association of Insomnia, Lipid Profile, and Lipid-Lowering Medications: A Narrative Review
by: Fang Jia, et al.
Published: (2025-01-01)

Anti-atherosclerotic effects of natural compounds targeting lipid metabolism and inflammation: Focus on PPARs, LXRs, and PCSK9
by: Marcella Palumbo, et al.
Published: (2025-03-01)

MicroRNA-1912 regulates cholesterol homeostasis by targeting PCSK9
by: Chan Joo Lee, et al.
Published: (2025-09-01)

Increased serum PCSK9 levels are associated with renal function impairment in patients with type 2 diabetes mellitus
by: Zhicai Feng, et al.
Published: (2023-12-01)

THE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) IN THE PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
by: Алексей Михайлович Чаулин, et al.
Published: (2019-12-01)

Outpatient Practice of Lipid-Lowering Therapy Prescription (According to the ARGO-3 Study)
by: M. V. Ezhov, et al.
Published: (2023-05-01)

PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines
by: A. A. Nekipelova, et al.
Published: (2023-09-01)

Value of proprotein convertase subtilisin/kexin type 9 and inflammatory markers in the diagnosis of carotid atherosclerosis in hypertensive men
by: Yu. Yu. Vukolova, et al.
Published: (2024-10-01)

Association of circulating proprotein convertase subtilisin/kexin type 9 concentration with coagulation abnormalities in patients with primary membranous nephropathy
by: Huizi Zhu, et al.
Published: (2023-12-01)

Relationship of sortilin and proprotein convertase subtilisin/kexin type 9 in blood serum with the severity of carotid and coronary atherosclerosis in hypertensive patients
by: Yu. Yu. Vukolova, et al.
Published: (2022-06-01)

The correlation between proprotein convertase subtilisin/kexin type 9 and adiponectin in the progression from prediabetes to type 2 diabetes mellitus
by: Jun-Xu Gu, et al.
Published: (2025-03-01)

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to tackle central nervous system diseases: role as a promising approach
by: Xiaoxiao Zheng, et al.
Published: (2025-07-01)

Discovery and SAR analysis of phenylbenzo[d][1,3]dioxole-based proprotein convertase subtilisin/kexin type 9 inhibitors
by: Fahui Li, et al.
Published: (2022-12-01)

Remnant Cholesterol and Residual Risk of Atherosclerotic Cardiovascular Disease
by: Xi Li, et al.
Published: (2025-02-01)

Atherosclerosis and inflammation: therapeutic targets and ways of correction
by: A. A. Klimenko, et al.
Published: (2024-06-01)

Evaluation of Intensive Statins and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Intracranial Artery Plaque Stability: A Prospective Single‐Arm Study
by: Weiqi Zeng, et al.
Published: (2025-01-01)

Efficacy and safety of different proprotein convertase subtilisin/kexin type 9 inhibitors in the general population and solid organ transplant recipients: a network meta-analysis
by: Bohan Luo, et al.
Published: (2025-08-01)

Exploring the therapeutic potential of precision medicine in rare genetic obesity disorders: a scientific perspective
by: Tinh-Hai Collet, et al.
Published: (2024-12-01)

Cholesteryl Ester Species but Not Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels Decline in Male Patients with Active Inflammatory Bowel Disease
by: Angelika Hettenbach, et al.
Published: (2025-03-01)

Modified Diagnostic Criteria Tools for Familial Hypercholesterolemia without the Requirement for Clinical Genetic Testing: Rationale and Design of the MOOCS Adaptive Clinical Trial
by: Satyanarayana Upadhyayula
Published: (2024-10-01)

Brazilin from Caesalpinia sappan L. as a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor: Pharmacophore-Based Virtual Screening, In Silico Molecular Docking, and In Vitro Studies
by: Muhammad Iqbal, et al.
Published: (2023-01-01)

Multimodal assessment of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors combined with statins for regulating coronary artery plaque regression in patients with chronic/acute coronary syndrome: A meta-analysis
by: Dexiao Yuan, et al.
Published: (2025-08-01)

Effect of immobilized hyaluronidase and subtilisin enzymes on the ultrastructure of human conjunctival epithelial cells
by: V. E. Zabanova, et al.
Published: (2023-02-01)

Association of Remnant-like Particle Cholesterol with Major Adverse Cardiovascular Events in Subjects with Different Levels of Proprotein Convertase Subtilisin/Kexin 9: A 9.5-year Follow-up Study in a Beijing Community Population
by: Xiaona Wang, et al.
Published: (2023-09-01)

Vasospastic angina — vasospastic myocardial infarction
by: A. S. Galyavich, et al.
Published: (2020-03-01)

Myocardial infarction and Turner syndrome
by: A. S. Galyavich, et al.
Published: (2019-04-01)

Overproduction of Tk-Subtilisin and Elucidation of Its Structural Thermostability Based on Molecular Dynamics Studies
by: Nouman Rasool, et al.
Published: (2025-07-01)

SUB6 Subtilisin is Involved During the Initial Adhesion of Trichophyton benhamiae and T. mentagrophytes onto Reconstructed Human Epidermis
by: Émilie Faway, et al.
Published: (2025-07-01)